Peter Droc News Today

Lonza Group AG / Key word(s): ExpansionLonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer 13.10.2023 / 08:00 CET/CEST The new cGMP filling line at Lonza’s Stein (CH) site will enable handling and filling of bioconjugates for commercial supply Expansion of fill...

Swiss CDMO Lonza has increased capacity and capabilities at its Visp, Switzerland site, with the completion of a new line for cGMP clinical and commercial drug product manufacturing.

Lonza Group AG / Key word: Expansion Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp 29.03.2023 / 09:00 CET/CEST Lonza increases capacity and... | March 29, 2023

Zhejiang Doer Biologics Co, Ltd and Lonza have entered into a research license agreement for Doer Biologics to use Lonza’s XS Technologies® offering for production of its proprietary MultipleBody® and SMART-VHHBody platform technology. Click to read more...

Lonza has signed a licensing agreement with clinical-stage biopharma, Zhejiang Doer Biologics, whereby the Hangzhou, China based biopharma company will develop multi-specific biotherapeutics using the Swiss CDMO’s XS Pichia.